Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
This Phase II study consists of 2 parts: 1) pre-screening phase and 2) treatment phase.
The pre-screening phase will investigate the presence of HRAS mutations in subjects with a
histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer
(SQ-NSCLC). Subjects may participate in the pre-screening phase at initial diagnosis or
following prior lines of therapy for SQ-NSCLC.
The treatment phase will investigate the antitumor activity in terms of ORR of tipifarnib in
subjects with locally advanced squamous non-small cell lung cancer (SQ-NSCLC) with HRAS
mutations and for whom there is no curative therapy available.